Lynavoy recommended for EU approval by the CHMP
RegulatorypositiveLynavoyPositive
AI Analysis
Summary
Lynavoy received a positive CHMP recommendation for EU approval as the first IBAT inhibitor for treating cholestatic pruritus in primary biliary cholangitis patients.
Outcome Details
CHMP positive recommendation for EU approval as first IBAT inhibitor for PBC cholestatic pruritus
Importance:8/10
Sentiment:
0.85
EU approvalCHMP recommendationfirst-in-classIBAT inhibitorPBCpruritus
Related Companies
Read the original article
Published by PharmaTimes on July 30, 2026 11:02 AM